SANASana Biotechnology, Inc.
$2.80-32% 1Y
$2.80
$2.6852 weeks$5.92
SANA in its own filings
Nothing in SANA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
105
Events found in the filings · across 389 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 8, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 8, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- SEC comment-letter activity10 occurrences
- 2025-09-10
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Corporate Presentation September 2026.Regulation FD disclosure · press release
- Aug 10, 2026Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
- May 15, 2026Sana Biotechnology, Inc. Date: May 15, 2026 By: /s/ Aaron M. Grossman Aaron M. Grossman Executive Vice President, Chief Legal Officer.Other event · Form 8-K
- May 11, 2026Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates.Earnings release · press release
- Apr 24, 2026In order to achieve a more equal balance of director membership among the three classes of the Board of Directors (“Board”) of Sana Biotechnology, Inc. (the “Company”) in accordance with the Company’s Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”), the Board determined that one of …Director or officer change · Form 8-K
- Apr 13, 2026On April 10, 2026 (the “Effective Date”), Sana Biotechnology, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Mayo Clinic, pursuant to which the Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares (the …Other event · Form 8-K
- Mar 3, 2026On March 3, 2026, the Company entered into an amended and restated sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) to sell shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), from time to time, through an “at the market offering” program under which TD …Earnings release · Form 8-K
- Feb 17, 2026Appointment of Executive Vice President, Chief Financial Officer, and Treasurer, and Transition of Principal Financial Officer On February 17, 2026, Sana Biotechnology, Inc. (the “Company”) announced that Brian Piper, M.B.A., joined the Company as Executive Vice President, Chief Financial Officer on February 17, 2026 …Director or officer change · Form 8-K
- Jan 14, 2026Sana has pioneered hypoimmune technology.Regulation FD disclosure · press release
- Nov 6, 2025Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates.Earnings release · press release
- Sep 5, 2025Sana Biotechnology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Current Report”) to disclose the planned retirement of Bernard J. Cassidy from his role as Executive Vice President, General Counsel, and Corporate Secretary.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…